Maximus Berger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/122112/publications.pdf

Version: 2024-02-01

29	929	13	26
papers	citations	h-index	g-index
30	30	30	1584
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Microbial Biotechnology, 2022, 16, 419-432.	1.7	9
2	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. Brain, Behavior, and Immunity, 2022, 99, 147-156.	4.1	2
3	Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis. Clinical Psychology Review, 2021, 86, 102005.	11.4	52
4	Relationship between allostatic load and clinical outcomes in youth at ultra-high risk for psychosis in the NEURAPRO study. Schizophrenia Research, 2020, 226, 38-43.	2.0	13
5	Harmonised collection of data in youth mental health: Towards large datasets. Australian and New Zealand Journal of Psychiatry, 2020, 54, 46-56.	2.3	8
6	Cross-sectional association of seafood consumption, polyunsaturated fatty acids and depressive symptoms in two Torres Strait communities. Nutritional Neuroscience, 2020, 23, 353-362.	3.1	8
7	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biological Psychiatry, 2020, 87, 243-252.	1.3	48
8	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. Schizophrenia Research, 2020, 226, 52-60.	2.0	8
9	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. Schizophrenia Research, 2020, 226, 44-51.	2.0	27
10	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. Behaviour Research and Therapy, 2020, 124, 103527.	3.1	16
11	Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Reports, 2020, 13, e235307.	0.5	16
12	Testing the Effects of Dietary Seafood Consumption on Depressive Symptoms. Methods in Molecular Biology, 2020, 2138, 233-242.	0.9	0
13	Novel Biological Treatment Strategies. , 2019, , 221-240.		0
14	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. Frontiers in Psychiatry, 2019, 10, 393.	2.6	22
15	Hair cortisol, allostatic load, and depressive symptoms in Australian Aboriginal and Torres Strait Islander people. Stress, 2019, 22, 312-320.	1.8	22
16	Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis. Psychoneuroendocrinology, 2018, 90, 35-42.	2.7	47
17	State marker properties of niacin skin sensitivity in ultra-high risk groups for psychosis - An optical reflection spectroscopy study. Schizophrenia Research, 2018, 192, 377-384.	2.0	12
18	Predictors of longer-term outcome in the Vienna omega-3 high-risk study. Schizophrenia Research, 2018, 193, 168-172.	2.0	6

#	Article	IF	CITATIONS
19	Screening for depression in young Indigenous people: building on a unique community initiative. Australian Journal of Primary Health, 2018, 24, 343.	0.9	6
20	Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis $\hat{a} \in \text{``Results of the randomized controlled Vienna omega-3 study. Schizophrenia Research, 2017, 188, 110-117.}$	2.0	23
21	Cortisol Awakening Response and Acute Stress Reactivity in First Nations People. Scientific Reports, 2017, 7, 41760.	3.3	35
22	Novel biotherapies are needed in youth mental health. Australasian Psychiatry, 2017, 25, 117-120.	0.7	13
23	Assessment of Insulin Resistance Among Drug-Naive Patients With First-Episode Schizophrenia in the Context of Hormonal Stress Axis Activation. JAMA Psychiatry, 2017, 74, 968.	11.0	26
24	8. Allostatic Load is Associated With Positive Symptoms in Schizophrenia and First-Episode Psychosis and Decreases With Antipsychotic Therapy. Schizophrenia Bulletin, 2017, 43, S9-S10.	4.3	0
25	Cortisol awakening response in patients with psychosis: Systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2016, 68, 157-166.	6.1	86
26	Allostatic load mediates the impact of stress and trauma on physical and mental health in Indigenous Australians. Australasian Psychiatry, 2016, 24, 72-75.	0.7	15
27	Mental health consequences of stress and trauma: allostatic load markers for practice and policy with a focus on Indigenous health. Australasian Psychiatry, 2015, 23, 644-649.	0.7	16
28	"More than skin deep― stress neurobiology and mental health consequences of racial discrimination. Stress, 2015, 18, 1-10.	1.8	385
29	Trauma and posttraumatic stress disorder in transcultural patients with chronic pain. Neuropsychiatrie, 2014, 28, 185-191.	2.5	8